Psilocybin

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi, most notably those in the genus Psilocybe. It belongs to the tryptamine class of compounds and is structurally similar to the neurotransmitter serotonin.

Chemical Structure

Psilocybin has the molecular formula C₁₂H₁₇N₂O₄P. Its structure consists of a tryptamine backbone with a phosphate group attached at the 4-position of the indole ring. This phosphate group makes psilocybin water-soluble and more stable than its active metabolite, psilocin.

Conversion to Psilocin

Psilocybin itself is not psychoactive. When ingested, it is rapidly dephosphorylated by alkaline phosphatase enzymes in the body, converting it to psilocin (4-hydroxy-N,N-dimethyltryptamine). This conversion primarily occurs in the acidic environment of the stomach and in the liver. Psilocin is the compound that actually crosses the blood-brain barrier and produces psychedelic effects by binding to serotonin receptors, particularly the 5-HT2A receptor.

Therapeutic Research Overview

Psilocybin has been the subject of extensive clinical research, particularly since the early 2000s. Key findings include:

• Depression: Johns Hopkins and Imperial College London studies have shown significant and lasting reductions in depression symptoms, with some participants experiencing remission after just 1-2 sessions.

• End-of-Life Anxiety: Research has demonstrated that psilocybin can reduce anxiety and depression in patients with terminal illness, often producing lasting improvements in quality of life and acceptance of death.

• Addiction: Studies have shown promise for treating tobacco addiction, alcohol use disorder, and other substance dependencies.

• PTSD: Early research suggests potential benefits for trauma-related conditions.

The FDA has granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression, accelerating the path toward potential approval.

Legal Status Note

Psilocybin remains a Schedule I controlled substance under federal law in the United States, meaning it is classified as having no accepted medical use and high potential for abuse. However, this classification is increasingly at odds with scientific evidence. Oregon became the first state to legalize psilocybin therapy in 2020 (Measure 109), and Colorado followed with Proposition 122 in 2022. Several cities have decriminalized psilocybin possession, and more states are considering similar measures. Internationally, legal status varies widely—some countries permit traditional use, while others maintain strict prohibition.